These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32851090)

  • 21. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.
    Youland RS; Pafundi DH; Brinkmann DH; Lowe VJ; Morris JM; Kemp BJ; Hunt CH; Giannini C; Parney IF; Laack NN
    J Neurooncol; 2018 May; 137(3):583-591. PubMed ID: 29330751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic approach for tumor delineation in glioma surgery: 3D MR spectroscopy image-guided resection.
    Zhang J; Zhuang DX; Yao CJ; Lin CP; Wang TL; Qin ZY; Wu JS
    J Neurosurg; 2016 Jun; 124(6):1585-93. PubMed ID: 26636387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
    Farina P; Tabouret E; Lehmann P; Barrie M; Petrirena G; Campello C; Boucard C; Graillon T; Girard N; Chinot O
    J Neurooncol; 2017 May; 132(3):433-437. PubMed ID: 28265824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging.
    Togao O; Hiwatashi A; Yamashita K; Kikuchi K; Keupp J; Yoshimoto K; Kuga D; Yoneyama M; Suzuki SO; Iwaki T; Takahashi M; Iihara K; Honda H
    Eur Radiol; 2017 Feb; 27(2):578-588. PubMed ID: 27003139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hierarchical non-negative matrix factorization to characterize brain tumor heterogeneity using multi-parametric MRI.
    Sauwen N; Sima DM; Van Cauter S; Veraart J; Leemans A; Maes F; Himmelreich U; Van Huffel S
    NMR Biomed; 2015 Dec; 28(12):1599-624. PubMed ID: 26458729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of
    Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.
    Santra A; Kumar R; Sharma P; Bal C; Kumar A; Julka PK; Malhotra A
    Eur J Radiol; 2012 Mar; 81(3):508-13. PubMed ID: 21353420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic performance of advanced MRI in differentiating high-grade from low-grade gliomas in a setting of routine service.
    Chawalparit O; Sangruchi T; Witthiwej T; Sathornsumetee S; Tritrakarn S; Piyapittayanan S; Chaicharoen P; Direksunthorn T; Charnchaowanish P
    J Med Assoc Thai; 2013 Oct; 96(10):1365-73. PubMed ID: 24350420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating diffusion kurtosis imaging, dynamic susceptibility-weighted contrast-enhanced MRI, and short echo time chemical shift imaging for grading gliomas.
    Van Cauter S; De Keyzer F; Sima DM; Sava AC; D'Arco F; Veraart J; Peeters RR; Leemans A; Van Gool S; Wilms G; Demaerel P; Van Huffel S; Sunaert S; Himmelreich U
    Neuro Oncol; 2014 Jul; 16(7):1010-21. PubMed ID: 24470551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade.
    Sahin N; Melhem ER; Wang S; Krejza J; Poptani H; Chawla S; Verma G
    Neuroradiol J; 2013 Oct; 26(5):531-41. PubMed ID: 24199813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Grading of Gliomas by Using Radiomic Features on Multiple Magnetic Resonance Imaging (MRI) Sequences.
    Qin JB; Liu Z; Zhang H; Shen C; Wang XC; Tan Y; Wang S; Wu XF; Tian J
    Med Sci Monit; 2017 May; 23():2168-2178. PubMed ID: 28478462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 11C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas.
    Li FM; Nie Q; Wang RM; Chang SM; Zhao WR; Zhu Q; Liang YK; Yang P; Zhang J; Jia HW; Fang HH
    Nucl Med Biol; 2012 Apr; 39(3):437-42. PubMed ID: 22172386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.
    Ng SH; Lin CY; Chan SC; Lin YC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Chang CJ; Wang JJ
    PLoS One; 2014; 9(12):e115933. PubMed ID: 25531391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging.
    Tietze A; Boldsen JK; Mouridsen K; Ribe L; Dyve S; Cortnum S; Østergaard L; Borghammer P
    Acta Radiol; 2015 Sep; 56(9):1135-44. PubMed ID: 25270372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients.
    Pirotte BJ; Levivier M; Goldman S; Massager N; Wikler D; Dewitte O; Bruneau M; Rorive S; David P; Brotchi J
    Neurosurgery; 2009 Mar; 64(3):471-81; discussion 481. PubMed ID: 19240609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.
    Kiviniemi A; Gardberg M; Frantzén J; Parkkola R; Vuorinen V; Pesola M; Minn H
    J Neurooncol; 2015 Sep; 124(2):237-45. PubMed ID: 26033547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic validity and reliability of BT-RADS in the management of recurrent high-grade glioma.
    Ebaid NY; Ahmed RN; Assy MM; Amin MI; Alaa Eldin AM; Alsowey AM; Abdelhay RM
    J Neuroradiol; 2024 Jun; 51(4):101190. PubMed ID: 38492800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
    Wang B; Zhao P; Zhang Y; Ge M; Lan C; Li C; Pang Q; Xu S; Liu Y
    J Neurooncol; 2018 Aug; 139(1):185-193. PubMed ID: 29696532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.